Canadian Cancer Trials Group Bulletins

General


Recent Publication

A publication related to Canadian Cancer Trials Group MA.17 (A Phase III Randomized Double Blind Study of Letrozole versus Placebo in Women with Primary Breast Cancer Completing Five or More Years of Adjuvant Tamoxifen), recently published online in Annals of Oncology, has found that extended letrozole after 5 years of tamoxifen is better than placebo in disease-free survival in both pre and postmenopausal women. Extended letrozole after 5 years of tamoxifen was effective in pre and postmenopausal women at diagnosis, and significantly better in those premenopausal. Women premenopausal at diagnosis should be considered for extended adjuvant therapy with letrozole if menopausal after completing tamoxifen.

Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Livingston RB, Davidson NE, Perez EA, Chavarri-Guerra Y, Cameron DA, Pritchard KI, Whelan T, Shepherd LE, Tu D. Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled Canadian Cancer Trials Group MA17 trial of extended adjuvant letrozole (ONLINE). Ann Oncol 2012.

http://annonc.oxfordjournals.org/content/early/2012/09/29/annonc.mds330.abstract

Canadian Cancer Trials Group MA.17, published in the Journal of the National Cancer Institute in 2005, showed improved outcomes in postmenopausal women given extended letrozole after completing 5 years of adjuvant tamoxifen.

Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from Canadian Cancer Trials Group MA.17. Journal of the National Cancer Institute:97(17):1262-1271,2005

http://jnci.oxfordjournals.org/cgi/content/abstract/97/17/1262